Dr. Patricia LoRusso on Next-Generation Sequencing Benefit in Metastatic Melanoma Treatment

Patricia M. LoRusso, DO
Published: Friday, Oct 16, 2015



Patricia M. LoRusso, DO, Professor of Medicine and Associate Director of Innovative Medicine, Yale Cancer Center, discusses taking a personalized medicine approach to treat melanoma patients whose tumors do not have BRAF alterations.

A trial, funded by both Stand Up 2 Cancer and the Melanoma Research Alliance investigated the use of next-generation sequencing technology to examine both the normal and cancer genome of patients with metastatic melanoma who have progressed on immunotherapy or can not use immunotherapeutic intervention.

Based on the results of the complex sequencing, treatment regimens are designed based on the individual molecular signatures of each patient’s tumor.



Patricia M. LoRusso, DO, Professor of Medicine and Associate Director of Innovative Medicine, Yale Cancer Center, discusses taking a personalized medicine approach to treat melanoma patients whose tumors do not have BRAF alterations.

A trial, funded by both Stand Up 2 Cancer and the Melanoma Research Alliance investigated the use of next-generation sequencing technology to examine both the normal and cancer genome of patients with metastatic melanoma who have progressed on immunotherapy or can not use immunotherapeutic intervention.

Based on the results of the complex sequencing, treatment regimens are designed based on the individual molecular signatures of each patient’s tumor.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x